More on Pfizer (PFE -0.6%) Q3: net profit falls to $3.21B from $3.74B. Sales -16%, hurt by forex and weaker than expected sales of Prevnar vaccine and Lipitor, which lost patent protection. Sales from key medicines, including Enbrel, Celebrex and Lyrica, continue to grow. Narrows FY EPS estimate to $2.14-$2.17 on revenue of $58B-$59B, both below consensus. Authorizes $10B buyback on completion of sale of nutrition business.